- Previous Close
1.6220 - Open
1.5800 - Bid 1.5360 x --
- Ask 1.5760 x --
- Day's Range
1.5340 - 1.5900 - 52 Week Range
0.7560 - 2.2500 - Volume
13,154 - Avg. Volume
95,817 - Market Cap (intraday)
109.338M - Beta (5Y Monthly) 0.36
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2800 - Earnings Date Feb 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.
www.sprintbioscience.comRecent News: SPRINT.ST
View MorePerformance Overview: SPRINT.ST
Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SPRINT.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SPRINT.ST
View MoreValuation Measures
Market Cap
109.34M
Enterprise Value
77.62M
Trailing P/E
5.84
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.81
Price/Book (mrq)
8.11
Enterprise Value/Revenue
1.29
Enterprise Value/EBITDA
3.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-31.10%
Return on Assets (ttm)
-20.45%
Return on Equity (ttm)
-82.55%
Revenue (ttm)
61.45M
Net Income Avi to Common (ttm)
-19.11M
Diluted EPS (ttm)
-0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
31.72M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-15.43M